PT  - JOURNAL ARTICLE
AU  - Jorge Luis Ramon-Patino
AU  - Sabine Schmid
AU  - Sally Lau
AU  - Lesley Seymour
AU  - Pierre-Olivier Gaudreau
AU  - Janice Juan Ning Li
AU  - Penelope Ann Bradbury
AU  - Emiliano Calvo
TI  - iRECIST and atypical patterns of response to immuno-oncology drugs
AID  - 10.1136/jitc-2022-004849
DP  - 2022 Jun 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e004849
VI  - 10
IP  - 6
4099  - http://jitc.bmj.com/content/10/6/e004849.short
4100  - http://jitc.bmj.com/content/10/6/e004849.full
SO  - J Immunother Cancer2022 Jun 01; 10
AB  - With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyperprogression, hypothesized to be a drug-induced acceleration of the tumor burden. Despite it being >10 years since the first immune-oncology drug was approved, neither the biology behind these paradoxical responses has been well understood, nor their incidence, identification criteria, predictive biomarkers, or clinical impact have been fully described. Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) guidelines have been published as a revision to the RECIST V.1.1 criteria for use in trials of immunotherapeutics, and the iRECIST subcommittee (of the RECIST Working Group) is working on elucidating these aspects, with data sharing a current major challenge to move forward with this unmet need in immuno-oncology.